Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, ...

Takeda offers strong cash flow, solid growth in key areas, and a 4.4% yield, but trades at a premium despite its fundamentals. Read why TAK stock is a hold.

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical ...

The positive results are a major leap forward for Takeda's orexin programme, which looked in jeopardy in 2021 when lead asset ...

Kenshi (Kenjustsu) vs Takeda (Shirai Ryu) Me Second Fight: 3:14 Takeda (Shirai Ryu) Me vs Shinnok (Imposter) Third Fight: ...

Costa Saroukos, who became Takeda’s global finance chief in 2018, discusses why moving fast after an acquisition is crucial in melding company cultures and cutting back debt.

Takeda Pharmaceutical reported a second-quarter net loss due to impairment losses on certain products and cut its net-profit forecast for the fiscal year ending March 2024.